The development of the production technology of (177)Lutetium trichloride

被引：0

作者：

Novikov, S. G. ^{[1
]}

Berintsev, A. V. ^{[1
]}

Alekseyev, A. S. ^{[1
]}

Svetukhin, V. V. ^{[1
]}

Kuznetsov, R. A. ^{[1
]}

Zhukov, A. V. ^{[1
]}

Fomin, A. N. ^{[1
]}

Kovalnogov, V. N. ^{[1
]}

Gorodetsky, V. G. ^{[2
]}

Karbolin, P. V. ^{[2
]}

Predeina, M. A. ^{[2
]}

Ivshin, S. A. ^{[2
]}

Ilyin, K. I. ^{[2
]}

Markov, D. V. ^{[2
]}

机构：

[1] Ulyanovsk State Univ, SP Kapitsa Res Inst Technol, Ulyanovsk, Russia

[2] JSC Inst Reactor Mat, Zarechnyi, Russia

来源：

JOURNAL OF COMPUTATIONAL METHODS IN SCIENCES AND ENGINEERING | 2018年 / 18卷 / 03期

关键词：

Technology; lutetium-trichloride-177; reactor irradiation; technological equipment; automated system;

D O I：

10.3233/JCM-180822

中图分类号：

T [工业技术];

学科分类号：

08 ;

摘要：

The results of the development of a new technological process and equipment for the production of trichloride-lutetium-177 at the JSC "Institute of Reactor Materials" are presented. A new technological process is proposed for the production of a radiopharmaceutical precursor of lutetium trichloride 177LuCl3, which comprises more than thirty technological and control operations. New technological equipment has been developed to ensure the implementation of technological operations within the process. The behavior modeling of the devices being developed in high-intensity radiation fields has been carried out.

引用

页码：709 / 713

页数：5

共 50 条

[31] Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176
Tarasov, Valery A.
Andreev, Oleg I.
Romanov, Evgeny G.
Kuznetsov, Rostislav A.
Kupriyanov, Vladimir V.
Tselishchev, Ivan V.
CURRENT RADIOPHARMACEUTICALS, 2015, 8 (02) : 95 - 106
[32] Standardization of the radiotherapy nuclide lutetium-177.
Zimmerman, BE
Unterweger, MP
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U85 - U85
[33] Production of GMP-compliant lutetium-177: radiochemical precursor for targeted cancer therapy
Chinol, Marco
Cutler, Cathy S.
Papi, Stefano
Ketring, Alan
Garaboldi, Lucia
Paganelli, Giovanni
Murray, Lory
NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 717 - 717
[34] The presence of the long-lived contaminant lutetium-177m in lutetium-177, used for radionuclide therapy in patients.
Bakker, WH
Kwekkeboom, DJ
de Jong, LC
Konijnenberg, MW
Janssen, PJ
Kooij, PP
Krenning, EP
JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 320P - 320P
[35] Lutetium Lu 177 vipivotide tetraxetan for prostate cancer
Liu, Xing
Fang, Gao-Chuan
Lu, Hao
Shi, Zhen-Duo
Chen, Zhe-Sheng
Han, Cong-Hui
DRUGS OF TODAY, 2023, 59 (01) : 37 - 49
[36] Lutetium Lu-177 Dotatate Flare Reaction
Salner, Andrew L.
Blankenship, Bette
Dunnack, Hayley
Niemann, Christopher
Bertsch, Helaine
ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (01)
[37] Theranostic Applications of Lutetium-177 in Radionuclide Therapy
Das, Tapas
Banerjee, Sharmila
CURRENT RADIOPHARMACEUTICALS, 2016, 9 (01) : 94 - 101
[38] Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
Susan J. Keam
Molecular Diagnosis & Therapy, 2022, 26 : 467 - 475
[39] Repeatability and stability evaluation of 177Lutetium quantification
Dekker, M. C.
Huizing, D. M. V.
de Wit-Van der Veen, B. J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S874 - S874
[40] Molecular and ionic clusters in saturated vapor over lutetium trichloride
Pogrebnoi, AM
Kudin, LS
Kuznetsov, AY
Butman, MF
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 1997, 11 (14) : 1536 - 1546

← 1 2 3 4 5 →